Nathan Bahary, MD
Medical Oncology · Pittsburgh, PANPI 1578535803
Payments from drug & device makers
Across 226 payments — averaging $9437.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$613K
- Eli Lilly$526K
- Exelixis Inc.$255K
- E.r. Squibb & Sons, L.L.C.$159K
- Corcept Therapeutics$106K
- Pfizer$102K
- plus $372K from 18 others
Across 6 payments — averaging $2365.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$12K
- F. Hoffmann-la Roche AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $613,146 |
| Eli Lilly | 8 | $526,028 |
| Exelixis Inc. | 70 | $254,989 |
| E.r. Squibb & Sons, L.L.C. | 3 | $159,042 |
| Corcept Therapeutics | 8 | $106,034 |
| Pfizer | 29 | $102,038 |
| AstraZeneca | 23 | $84,157 |
| Ipsen Bioscience Inc. | 9 | $78,950 |
| Roche Products Limited | 10 | $47,593 |
| Ipsen Biopharmaceuticals, Inc | 4 | $42,950 |
| Halozyme Inc | 5 | $40,695 |
| Regeneron | 1 | $31,000 |
| GSK | 7 | $23,951 |
| Incyte Corporation | 10 | $6,554 |
| Mirati Therapeutics, Inc. | 4 | $6,500 |
| Bristol Myers Squibb | 2 | $3,048 |
| Amgen | 1 | $2,744 |
| Array Biopharma Inc | 2 | $2,025 |
| Taiho Oncology, Inc. | 1 | $1,137 |
| AbbVie | 6 | $105 |
| Genentech, Inc. | 1 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Sanofi | 1 | $21 |
| Tempus AI, Inc | 1 | $14 |
How this compares
$2,132,791 in reported general payments places this provider in the 85th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Pittsburgh
- Adam BrufskyPittsburgh$6M
- John KirkwoodPittsburgh$3.4M
- Melissa BurgessPittsburgh$2.4M
- Jane RaymondPittsburgh$794K
- Ariel Lopez-ChavezPittsburgh$727K
- Ashwin SomasundaramPittsburgh$696K
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
- Kim Reiss BinderPhiladelphia$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.